Biogen Thwarts 'Brazen' Drug Copycat With IP Settlement
Biogen Inc. has secured a settlement blocking what it called a New York bioscience company's "brazen" effort to sell copycat versions of its potential blockbuster Alzheimer's drug, according to a Wednesday...To view the full article, register now.
Already a subscriber? Click here to view full article